Free Trial
NASDAQ:GANX

Gain Therapeutics Q2 2024 Earnings Report

Gain Therapeutics logo
$1.99 +0.11 (+5.85%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.01 +0.02 (+1.21%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

Gain Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gain Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Gain Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gain Therapeutics Earnings Headlines

HC Wainwright Cuts Earnings Estimates for Gain Therapeutics
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
Gain Therapeutics Reports Q2 2025 Financial Results
See More Gain Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email.

About Gain Therapeutics

Gain Therapeutics (NASDAQ:GANX), a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

View Gain Therapeutics Profile

More Earnings Resources from MarketBeat